Argos Therapeutics Inc (NASDAQ:ARGS) shares rose 11% during mid-day trading on Wednesday . The company traded as high as $2.70 and last traded at $2.42. Approximately 1,012,300 shares traded hands during mid-day trading, an increase of 148% from the average daily volume of 407,553 shares. The stock had previously closed at $2.18.
The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29.
Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.00) earnings per share (EPS) for the quarter.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.